AU3111995A - Pharmaceutical compositions comprising a chimaeric tnf binding protein - Google Patents

Pharmaceutical compositions comprising a chimaeric tnf binding protein

Info

Publication number
AU3111995A
AU3111995A AU31119/95A AU3111995A AU3111995A AU 3111995 A AU3111995 A AU 3111995A AU 31119/95 A AU31119/95 A AU 31119/95A AU 3111995 A AU3111995 A AU 3111995A AU 3111995 A AU3111995 A AU 3111995A
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
binding protein
tnf binding
chimaeric
chimaeric tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31119/95A
Other languages
English (en)
Inventor
Robert Fredrick Geoffrey Booth
Werner Lesslauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU3111995A publication Critical patent/AU3111995A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU31119/95A 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein Abandoned AU3111995A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94111455 1994-07-22
EP94111455 1994-07-22
PCT/EP1995/002788 WO1996003141A1 (en) 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein

Publications (1)

Publication Number Publication Date
AU3111995A true AU3111995A (en) 1996-02-22

Family

ID=8216138

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31119/95A Abandoned AU3111995A (en) 1994-07-22 1995-07-15 Pharmaceutical compositions comprising a chimaeric tnf binding protein

Country Status (11)

Country Link
EP (1) EP0772449A1 (fi)
JP (1) JPH09508140A (fi)
AU (1) AU3111995A (fi)
BR (1) BR9508419A (fi)
CA (1) CA2195665A1 (fi)
CZ (1) CZ283219B6 (fi)
FI (1) FI970247A0 (fi)
HU (1) HUT76666A (fi)
NO (1) NO970264L (fi)
PL (1) PL318501A1 (fi)
WO (1) WO1996003141A1 (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
CN1233189A (zh) * 1996-05-08 1999-10-27 弗·哈夫曼-拉罗切有限公司 用TNFR-Ig治疗哮喘
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP0948543A1 (en) * 1996-12-12 1999-10-13 Genentech, Inc. Hvem polypeptides and uses thereof
ATE250784T1 (de) 1998-11-27 2003-10-15 Synaptics Uk Ltd Positionssensor
CZ20032208A3 (cs) 2001-02-23 2004-01-14 Immunex Corporation Zvýšený výtěžek aktivních proteinů
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
WO2003066165A1 (en) 2002-02-06 2003-08-14 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1994008609A1 (en) * 1992-10-15 1994-04-28 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION

Also Published As

Publication number Publication date
HUT76666A (en) 1997-10-28
JPH09508140A (ja) 1997-08-19
CZ283219B6 (cs) 1998-02-18
NO970264L (no) 1997-03-24
FI970247A (fi) 1997-01-21
BR9508419A (pt) 1997-11-18
WO1996003141A1 (en) 1996-02-08
NO970264D0 (no) 1997-01-21
CA2195665A1 (en) 1996-02-08
EP0772449A1 (en) 1997-05-14
FI970247A0 (fi) 1997-01-21
PL318501A1 (en) 1997-06-23
CZ19397A3 (en) 1997-06-11

Similar Documents

Publication Publication Date Title
AU2662795A (en) Cdk4 binding proteins
AU3559695A (en) Glycosylated protein-liposome conjugates and methods for their preparation
AU5283793A (en) Recombinant specific binding protein
AU3111995A (en) Pharmaceutical compositions comprising a chimaeric tnf binding protein
AU7175694A (en) Lipopolysaccharide binding protein derivatives
AU7113896A (en) Tumor derived carbohydrate binding protein
AU4407797A (en) Pharmaceutical composition forming a gel
AU5155096A (en) Pharmaceutical composition
AU2531295A (en) Pharmaceutical composition
AU5740194A (en) A bone sialoprotein binding protein as well as its preparation
AU8596498A (en) Annexin binding protein
AU2186895A (en) Polypeptides of lipopolysaccharide binding protein
AU1750997A (en) Obesity protein formulations
AU5384596A (en) Binding assembly
AU1705197A (en) Obesity protein formulations
AU3640397A (en) Ob protein binding protein
AU7410598A (en) Novel human RNA binding protein
AU2287595A (en) Class i peptide binding motifs
AU1747297A (en) Obesity protein formulations
AU1475595A (en) Pharmaceutical preparation
AU4586497A (en) Calcium-integrin binding protein
AU8063298A (en) Human formin binding protein
AU1427895A (en) Pharmaceutical compositions
AU1544195A (en) Pharmaceutical compositions
AU6569998A (en) Obesity protein formulations